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signiﬁcant difference against CD20- control cells: RS4;11 and
Jurkat.
Consistently, intracellular CD107a degranulation was
enhanced in CAR+ exPBNK compared to CAR- exPBNK in
response to CD20+ Ramos.
MIC expressionwas signiﬁcantly increased in Ramos (P< .05)
and in NALM-6 (P < .001) after romidepsin treatment.
CD20 expression was signiﬁcantly increased in NALM-6 (P <
.001) after romidepsin treatment.
CAR+ exPBNK in vitro cytotoxicity was signiﬁcantly enhanced
against romidepsin treated Ramos (P< .02) and NALM-6 (P<
.01) compared to untreated targets.
Conclusion: Anti-CD20 CAR expression in exPBNK cells
results in signiﬁcant and speciﬁc in vitro cytotoxicity against
CD20+ B-L/L. Romidepsin increases MICA/B and CD20
expression in B-L/L. CAR exPBNK signiﬁcantly enhanced
cytotoxicity against romidepsin treated B-L/L. Future direc-
tions include examining the combination effect of CAR
exPBNK and Romidepsin against B-L/L in xenograft mice.411
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T cell depletion (TCD) by negative or positive selection
reduces graft-vs-host disease and its complications while
maintaining relapse free survival in appropriately selected
patients. Differences in acute GVHD incidence of sibling
donor transplants using 3 TCDmethods stimulated review of
graft content. Graft source (bone marrow [BM] or peripheral
blood stem cells [PBSC]) and TCD method determine cell
composition, impacting outcome and survival. As a center
historically committed to TCD, we reviewed 531 TCD grafts
processed in 2000-2011 using 3 TCD methods for BM or
PBSC. Pre and postprocessing cell composition, log10 TCD,
and % CD34+ recovery were compared. BM, negatively
selected by soybean lectin agglutination and sheep RBC
rosetting (SBA-E-) was used in 76 patients; PBSC, positively
selected for CD34+ cells by the Isolex followed by RBCTable
Median Cell Dose/kg Pre and Post TCD
Cells TNC CD34 CD3
Pre BM 3.81E+08 5.87E+06 2.69E+07
Pre PBSC 1.19E+09 8.72E+06 2.38E+08
SBA-E- 2.84E+07 1.86E+06 6.07E+04
Iso E- 7.63E+06 7.31E+06 1.58E+03
Clini 8.53E+06 1.05E+07 3.56E+03rosetting (IsoE-) for 361 patients, or by the CliniMACS (Clini),
for 94 patients. The table shows preprocessing cell doses and
phenotypic proﬁle were signiﬁcantly different between pre
BM and pre PBSC for TNC, CD3+T cells, T cell subsets, NK cells
and CD34+ (P-values < .001, Wilcoxon rank-sum test). BM T
cells had a 1:1 ratio of CD4:CD8 while PBSC had a 1:2 ratio.
The table shows post TCD T cell doses were signiﬁcantly
higher in BM than in PBSC grafts. In TCD BM, the median log
10 depletion of CD3 + T cells (2.65) was signiﬁcantly different
from IsoE log10 TCD (5.22). Clini log 10 TCD (4.92) was
similar to IsoE. Strikingly, while preprocessed BM had fewer
NK CD56/16+ than PBSC (3.86E+06 vs. 3.59E+07), the nega-
tive selection of BM left more NK cells in the TCD graft,
resulting in signiﬁcantly higher NK cell dose (6.73E+05) than
after CD34+ positive selection by Iso E- (2.25E+03) or Clini
(6.98E+02). IsoE- had signiﬁcantly (P < .001) higher CD34
doses (7.31E+06 /kg) and greater recovery (85.0%) of CD34+
cells; than SBA-E- (1.86E+06 /kg, 33.3% recovery). Clini
selection resulted in similar CD34 cell doses and recovery to
the IsoE-. (1.05E+07/kg, 116.74 % recovery). Number and
types of CD3+ T cells, T subpopulations, NK, and CD34+ in
TCD grafts act in concert with donor and host parameters to
effect ﬁnal transplant outcome. Characterization of cells in
preprocessed grafts and retained by TCDmethods can lead to
better graft engineering and optimization of the cellular
content of the ﬁnal T depleted product.412
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Table
Median Cell Dose/kg Pre and Post TCD
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The impact of the years of storage of an umbilical cord blood
unit (CBU) on its engraftment potency is not known. We
analyzed engraftment kinetics of 15 Old CBUs deﬁned as
stored for more than 5 years and compared it to 71 Younger
CBUs for end points of time to neutrophil and platelet
engraftment. The median duration of storage for the Old
CBUs was 5.6 years (5.6-12.2 years). For Old vs. Young CBUs,
the average total nucleated count was 0.5 x106 vs. 55x106 (P
¼ .004), cryopreservation volume of 72ml vs. 70ml (P ¼ .9),
CD34 count of 0.19x106/kg vs. 0.23x106/kg (P ¼ .7). There
were no differences in the processing of the CBUs. The donor
characteristics for the Old vs. Young CBUs were Caucasian
race: 7% vs. 24% (P < .0001)and female sex: 43% vs. 49% (P ¼
.3). The recipient characteristics for the Old vs. Young CBUs
were: female sex: 57% vs. 45% (P ¼ .4), Caucasian race 43% vs.
63% (P < .0001), recipient weight 30kg vs. 38kg (p¼NS),
recipient age 14 vs. 16 years (p¼NS). The transplant condi-
tioning, GVHD prophylaxis and degree of HLA mismatch was
comparable for the two groups. There were no differences in
the engraftment kinetics for the Old vs. Young CBUs with
time to neutrophil engraftment of 21 vs. 22 days (P ¼ .5);
platelet engraftment of 43 vs. 42 days (P ¼ .3). Early deaths
were comparable 7% vs. 6%, no differences were noted in the
duration of hospitalization. We conclude that Old CBUs
should remain as a potential source of stem cells.414
IL-15 Alone Supports in Vitro Generation of Polyclonal
CTL From CD3/CD28 Co-Stimulated Expanded CB T Cells
Against Leukemia Cells
Jeyaraj Antony 1, Xiaohua Chen 2, Paul Szabolcs 3. 1 Pediatrics,
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA;
2 pediatrics, Children's Hospital of Pittsburgh of UPMC,
pittsburgh, PA; 3 University of Pittsburgh
Background: Ex vivo expanded CBTcells (with CD3/CD28 co-
stimulatory beads + IL-2 and IL-7) are receptive to subse-
quent in vitro priming against killed lymphoid and myeloid
leukemia cells in the presence of IL-7, IL-12, and IL-15. This
had been reported from our lab (Davis et al. Cancer Research
2010, 70(13): 5249).
Objectives:We tested 1) the minimum cytokine and priming
requirements, hypothesizing that higher speciﬁcity may be
obtained if fewer exogenous cytokine is employed. 2)
Determine the critical recognition element of cytotoxicity. 3)
Characterize the cellular phenotype associated with the CTL
activity.
Methods: CTL was generated from already expanded (<3% of
a typical cord blood graft) >98% pure T cells either with
a combination of cytokines IL-7, -12 & -15 (n¼4) versus IL-15
(n¼5), versus IL-7 (n¼3) alone. After 2nd and 3rd weeks of
CTL cultures, the cytotoxicity was tested against fresh IM9
leukemia cells using europium ligand (EuTDA) release assay.
The blocking with HLA class I & II and TCRgd antibodies were
done before performing the CTL assay (n¼3). ELISPOT assay
was done to test the speciﬁcity as measured by IFN-g spot
forming cells (SFC). Eight colors FACS analysis was done
using FACS canto II, to analyze the CTL's phenotype.
Results: After 3 weeks of priming, the mean speciﬁc lysis of
CTL generated using IL-15 alone versus combination of
cytokines on fresh IM9 cells was 79% and 80% respectively at
an E/T ratio of 40:1 (Figure-1). CTL generated using IL-15
alone has a speciﬁc lysis of 90% at the end of second priming
(n¼4). The CTL's exhibit no cytotoxicity against non-speciﬁc
targets (myeloid leukemia cell line U937). The expanded CBT
cells primed with IL-15 alone, but without being exposed to
IM9 cells did not acquire speciﬁc cytotoxicity (n¼4). While
cytotoxicity was comparable, CTL from IL-15 alone cultures
displayed higher speciﬁcity in ELISPOTassays with much less
non-speciﬁc target recognition as measured by IFN-g spot
forming cells (SFC) (n¼2).
Eventhough, no single blockingMoAb completely abolished
cytotoxicity, the most signiﬁcant diminution was identiﬁed
when the effectors were blocked with TCRgd. Multicolor
FACS analysis indicates that after exposing the CTLs to
speciﬁc targets, w6-7% of the cells are secreting IFN-g in
response and 6-20% are TCRgd positive. Immunoscope
analysis of TCRgd spectratype identiﬁes oligoclonal restric-
tion of CTL cultures with lytic activity compared to identical
cytokine expanded T cells lacking leukemiaespeciﬁc CTL
activity.
